1 company and 1 research report found for "Egalet Corporation"
No sector reports have been found.
In late December, Egalet submitted an NDA for its Arymo ER abuse-deterrent (AD) morphine tablet – a widely prescribed opiate with few AD competi...
Forgotten your login?
Registered office: Edison Investment Research Limited, 280 High Holborn, London, WC1V 7EE UK. Company no. 4794244. VAT no. 815041270
© 2017 All rights reserved. Edison Investment Research is authorised and regulated by the Financial Conduct Authority.
This site requires cookies in order to give you the best user experience.
Find out more